Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ProQR Therapeutics (PRQR) Debt to Equity (2016 - 2025)

ProQR Therapeutics' Debt to Equity history spans 6 years, with the latest figure at $0.1 for Q4 2025.

  • On a quarterly basis, Debt to Equity rose 90.72% to $0.1 in Q4 2025 year-over-year; TTM through Dec 2025 was $0.1, a 90.72% increase, with the full-year FY2025 number at $0.1, up 90.72% from a year prior.
  • Debt to Equity hit $0.1 in Q4 2025 for ProQR Therapeutics, up from $0.05 in the prior quarter.
  • Over the last five years, Debt to Equity for PRQR hit a ceiling of $0.43 in Q2 2022 and a floor of $0.05 in Q4 2024.
  • Historically, Debt to Equity has averaged $0.17 across 5 years, with a median of $0.1 in 2022.
  • Biggest five-year swings in Debt to Equity: soared 200.89% in 2022 and later tumbled 84.04% in 2023.
  • Tracing PRQR's Debt to Equity over 5 years: stood at $0.39 in 2021, then tumbled by 73.72% to $0.1 in 2022, then increased by 2.12% to $0.1 in 2023, then plummeted by 50.11% to $0.05 in 2024, then soared by 90.72% to $0.1 in 2025.
  • Business Quant data shows Debt to Equity for PRQR at $0.1 in Q4 2025, $0.05 in Q4 2024, and $0.1 in Q4 2023.